2ND ANNUAL
KASBP NJ/NY CHAPTER
BIOPHARMA CONFERENCE 2026

From Unmet Need to Patient Access

A One-Day Journey of Drug Development

Co-Hosted with SK Biopharmaceuticals
(XCOPRI Case Study)

Saturday, Oct. 10th, 2026

NEW JERSEY • NEW YORK

KASBP NJ/NY
Korean American Society in Biotech and Pharmaceuticals
NEW JERSEY / NEW YORK

SK biopharmaceuticals

WELCOME TO THE 2ND KASBP NJ/NY CHAPTER BIOPHARMA CONFERENCE

Dear Distinguished Guests, Colleagues, and KASBP Members,



It is my great honor to welcome you to the 2nd KASBP NJ/NY Chapter Conference, From Unmet Need to Patient Access: A One-Day Journey of Drug Development, co-hosted with SK Biopharmaceuticals.

For a long time, I have wanted to tell the complete story of how a new drug is developed and finally reaches patients, from beginning to end, in a single day. Then I came across a Korean pharmaceutical company whose journey embodies that entire story, and I began to think that, together with the experts in our community, we could turn that idea into something real.

Looking back at my own early years in the lab, I remember not knowing exactly where my research would lead. I hope today gives every attendee, however far along your own path, a chance to see how discovery, clinical development, regulatory approval, and commercialization all connect into one continuous journey.

Today, we will first see how academic researchers, clinicians, and industry leaders each look at a single disease from their own vantage point. Through our regulatory and commercial experts, we will then follow how that work moves through the middle and later stages of drug development to finally reach patients. And to close, we will hear the reflections of the person leading this entire journey.

I am deeply grateful to SK Biopharmaceuticals for partnering with us to bring this conference to life, and to every speaker who took the time to be here. Thank you also to our organizing committee members and volunteers, and to all of you for joining us.

This started as a small idea, and it is a genuine pleasure to see it come together. I hope today is an inspiring and memorable day for you all.

Warm regards,
Min Suk Kang, Ph.D
President, KASBP NJ/NY Chapter

CONGRATULATORY MESSAGE FROM CEO OF SK BIOPHARMACEUTICALS



Dear guests, colleagues, and KASBP members,

It is a great pleasure to warmly welcome all of you to the KASBP NJ/NY Biopharma Conference.

This year is especially meaningful as it marks the first collaboration between SK Biopharmaceuticals and KASBP NJ/NY.
I would like to sincerely express my appreciation to Dr. Min Suk Kang, the KASBP leadership team, the distinguished speakers, and all of you for joining us today.

As we all know, the biopharmaceutical industry is built on innovation. Yet the innovative breakthroughs are rarely achieved alone. They are born through collaboration, partnership, and accelerated through the open exchange of knowledge and ideas. This is precisely why today's conference matters.

Throughout the day, we will explore perspectives spanning the entire innovation journey, from addressing unmet patient needs and driving scientific discoveries to clinical development, commercialization, and business development. Especially, we are delighted to highlight the journey of XCOPRI, a medicine developed by SK Biopharmaceuticals, as a meaningful case study. We hope that sharing both our achievements and the lessons we have learned along the way will enrich today’s discussions and provide valuable insights for all participants.

I also hope that today’s conference serves not only as a forum for learning, but as a platform for building lasting and meaningful connections. The New Jersey and New York region is home to one of the world's most dynamic biopharmaceutical ecosystems, and I firmly believe that the relationships formed here today will help shape future innovation, collaboration, and growth across our industry.

On behalf of SK Biopharmaceuticals, thank you once again for being with us. I wish you an engaging, productive, and inspiring conference.

Thank you.

Sincerely,
Donghoon Lee
CEO, SK Biopharmaceuticals & SK Life Science Inc.

CONGRATULATORY MESSAGE FROM THE KASBP PRESIDENT



Dear guests, colleagues, and fellow KASBP members,

Thank you to everyone attending the 2026 KASBP NJ/NY Chapter Biopharma Conference.

My name is Min-Kyu Cho, and as the 23rd President of KASBP, it is my great privilege to send my warmest greetings to this wonderful gathering.

I would like to express my sincere appreciation to Chapter President Min Suk Kang, the organizing committee, and all the speakers and panelists for their dedication and hard work in preparing this exceptional conference. I also extend my deepest gratitude to SK Biopharmaceuticals for co-hosting and generously supporting this event.

This year's theme, "From Unmet Need to Patient Access: A One-Day Journey of Drug Development," highlights the very heart of our mission as pharmaceutical professionals. Our ultimate goal goes beyond discovering a breakthrough molecule in the lab; it is about delivering that innovation through clinical, regulatory, and commercial pathways directly into the hands of patients. I am confident that today's comprehensive sessions, spanning R&D, clinical development, and market access – will offer profound insights and fresh inspiration for everyone, from seasoned experts to early-career researchers.

Since its founding in New Jersey in 2001, KASBP has served as a vital bridge connecting the biopharmaceutical industries of Korea and the United States. Building on this legacy, KASBP will proudly celebrate its 25th anniversary in Newark, NJ, this coming November.

I hope today's conference provides you with meaningful connections, insightful discussions, and lasting networks. Thank you for your continued interest in and unwavering support of KASBP.

Sincerely,
Min-Kyu Cho
23rd President of KASBP

Pre-Event Networking & Refreshments

- 9:00AM - 10:00AM — REGISTRATION & NETWORKING

Opening Ceremony

Moderator: Jungwon Wee, Manager, SK Biopharmaceuticals

- 10:00AM - 10:05AM — OPENING REMARKS
  Min Suk Kang, Ph.D.
  KASBP NJ/NY Chapter President,
  Columbia University Irving Medical Center
- 10:05AM - 10:10AM — CONGRATULATORY REMARKS
  Jong Sung Koh, Ph.D.
  CEO, Genosco Inc.

Session I
Creating Innovation: Discovery & R&D (KEYNOTE)

- 10:10AM - 10:50AM — **Libor Velisek, M.D., Ph.D., FAES**
  Assistant Dean for Basic Medical Sciences, School of Medicine, Professor, Cell and Molecular Physiology (Division of Neuroscience), Neurology, and Pediatrics, Director, MD-PhD Program, New York Medical College

"Epilepsy as a challenge for pharmacotherapy development"

- 10:50AM - 11:30AM — **Hai Sun, M.D., Ph.D.**
  Vice Chair of Clinical Operations and Professor in Neurosurgery and Neurology
  Rutgers Robert Wood Johnson Medical School

"The Surgical Management of Drug-Resistant Epilepsy"

- 11:30AM - 11:50AM — COFFEE BREAK

Session I
Creating Innovation: Discovery & R&D (Cont.)

- 11:50AM - 12:20PM — **Haein Shin**
  Vice President, Portfolio, SK Biopharmaceuticals

Science & Serendipity: Five Pivotal Moments in the Cenobamate (XCOPRI®) Journey from Discovery to IND

- 12:20PM - 1:30PM — GROUP PHOTO & NETWORKING LUNCH

CONGRATULATORY REMARKS

Min-Kyu Cho, Ph.D.
KASBP *President, GSK*

Session II Translating Innovation:
Clinical Development & Regulatory Approval

- 1:30PM - 2:00PM — **Sangmok Chung, Ph.D.**
  President, NatureCell America

"The Drug Development Odyssey: Clinical and Regulatory Perspectives"

- 2:00PM - 2:30PM — **Sunita Misra, M.D., Ph.D.**
  Chief Medical Officer, SK Life Science Inc.

"EXPECT THE UNEXPECTED (Lessons in Scientific Adaptability from the Clinical Development of Cenobamate)"

- 2:30PM - 2:50PM — COFFEE BREAK

Session III Delivering Innovation:
Commercialization, Market Access & Beyond

- 2:50PM - 3:10PM — **Kristina Stracco**
  Vice President, Market Access, SK Life Science Inc.

"From Manufacturer to Patient: Navigating the Complex Pathways to Market Access"

- 3:10PM - 3:30PM — **Keunyong Cho**
  Vice President, Commercial Operations, SK Life Science Inc.

"From Discovery to U.S. Commercialization: The XCOPRI® Journey"

- 3:30PM - 3:50PM — **Woojin Choi**
  Vice President, U.S. Business Development, SK Life Science Inc.

"Effectively Utilizing Strategic Initiatives (BD) to Unlock Additional Growth"

Closing Keynote

- 3:50PM - 4:20PM — **Donghoon Lee**
  CEO, SK Biopharmaceuticals & SK Life Science Inc.

Networking Reception Party

- 4:30PM - 6:30PM — NETWORKING
  (Raffle Drawing at 5 pm)

CREATING INNOVATION: DISCOVERY & R&D (KEYNOTE)

"Epilepsy as a challenge for pharmacotherapy development"



Libor Velisek, M.D., Ph.D., FAES

Assistant Dean for Basic Medical Sciences, School of Medicine
Professor, Cell and Molecular Physiology (Division of Neuroscience),
Neurology, and
Pediatrics
Director, M.D.-Ph.D. Program
New York Medical College

Epilepsy is not a single disease, but a heterogeneous group of disorders with distinct etiologies, mechanisms, developmental trajectories, and therapeutic requirements. This heterogeneity presents a fundamental challenge for therapy development: there is no single “silver bullet” capable of treating all epilepsies. Indeed, many currently available antiseizure medications may be highly effective in one type of epilepsy, yet less effective or even detrimental in another. Moreover, in many epilepsies the disease process evolves through epileptogenesis, creating therapeutic opportunities and challenges that extend well beyond symptomatic seizure suppression. Although seizure control remains essential, it represents only one goal of treatment development and, conceptually, perhaps the most accessible one. Future therapies should increasingly pursue disease modification, altering the underlying course of epilepsy and its associated neurodevelopmental consequences and comorbidities. Ultimately, treatment strategies should also target antiepileptogenesis, with interventions designed to delay or prevent the development of epilepsy after an initiating insult or during a defined disease process.

Developmental epilepsies present a particularly demanding challenge because the therapeutic target is not merely suppression of the seizure occurring today, but interruption of processes that generate recurrent seizures while simultaneously compromising the developing brain. Over the past two decades, our laboratory has focused on developing experimental tools for studying severe developmental and epileptic encephalopathies, particularly infantile epileptic spasms syndrome (IESS), and more recently its progression to Lennox-Gastaut syndrome (LGS). Returning to the issue of heterogeneity, even IESS is not a unitary disorder: it may arise from hundreds of different etiologies and may ultimately require treatments tailored, if not to individual causes, then to biologically meaningful etiologic or mechanistic subgroups. Similarly, progression from IESS to LGS is not uniform. Our current research seeks to develop reliable models of IESS and to define the conditions and mechanisms of underlying progression to an LGS-like phenotype. Such disease-relevant models, while necessarily imperfect representations of the human condition, can provide critical tools for evaluating therapeutic mechanisms, defining appropriate targets and developmental windows for intervention, and reducing translational missteps that may accompany accelerated development of new treatments.

Biography

Libor Velisek, M.D., Ph.D., FAES, is Professor of Cell and Molecular Physiology, Pediatrics, and Neurology at New York Medical College, where he also serves as Assistant Dean for Basic Sciences in the School of Medicine and Director of the MD-PhD Program. A developmental neuroscientist and epilepsy researcher, Dr. Velisek has spent more than three decades investigating the mechanisms and treatment of developmental epilepsies and epileptic encephalopathies, with particular emphasis on infantile epileptic spasms syndrome and its progression to Lennox-Gastaut syndrome. His research, supported by the NIH, private foundations, and industry, integrates translational animal models, electrophysiology, pharmacology, and neuromodulation to identify disease mechanisms, validate therapeutic targets, and evaluate emerging treatment strategies for severe childhood epilepsies. He is a Fellow of the American Epilepsy Society and has held longstanding leadership and editorial roles in epilepsy research, neuroscience, and medical education.

The Surgical Management of Drug-Resistant Epilepsy



Hai Sun, M.D., Ph.D.
Vice Chair of Clinical Operations and Professor in Neurosurgery and Neurology
Rutgers Robert Wood Johnson Medical School

Epilepsy is a common neurological disorder associated with substantial morbidity and mortality. Despite advances in antiseizure medications, approximately one-third of patients develop drug-resistant epilepsy. For appropriately selected patients, epilepsy surgery offers an important yet underutilized treatment option.

This presentation provides an overview of the principles and contemporary practice of epilepsy surgery, focusing on patient selection, presurgical evaluation, localization of the epileptogenic zone, and treatment strategies. Patients who continue to experience seizures despite trials of two appropriate antiseizure medications should be considered for comprehensive surgical evaluation. Presurgical assessment integrates seizure semiology, long-term video-EEG monitoring, high-resolution MRI, neuropsychological testing, and functional imaging, including PET, SPECT, and functional MRI. When noninvasive studies are insufficient, invasive intracranial monitoring, particularly stereo-EEG, may be required.

Treatment is individualized through multidisciplinary evaluation to maximize seizure control while minimizing neurological and cognitive risks. Surgical resection or ablation may provide seizure freedom in appropriately selected patients, while neuromodulatory therapies—including vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation—offer alternatives for patients who are not candidates for definitive resection.

Biography
Hai Sun, M.D., Ph.D., is Professor of Neurosurgery and Neurology at Rutgers Robert Wood Johnson Medical School, where he serves as Vice Chair of Clinical Operations, Chief of Neurosurgery at Robert Wood Johnson University Hospital, and Director of Epilepsy Surgery. He earned his M.D. and Ph.D. in Biomedical Engineering from Dartmouth College and completed neurosurgical residency at Oregon Health & Science University, followed by fellowships in epilepsy, cerebrovascular/skull base, and endovascular neurosurgery.

Dr. Sun specializes in epilepsy surgery and the surgical treatment of brain tumors and cerebrovascular disorders. His research focuses on epilepsy pathophysiology, neuromodulation, neuroimaging, brain networks, and traumatic brain injury. He has authored more than 100 peer-reviewed publications and book chapters, and his research is supported by the National Institutes of Health and U.S. Department of Defense.

Science & Serendipity: Five Pivotal Moments in the Cenobamate (XCOPRI®) Journey from Discovery to IND



Haein Shin
Vice President, Portfolio
SK Biopharmaceuticals

Epilepsy is a chronic neurological disorder characterized by recurrent seizures resulting from abnormal electrical activity in the brain, affecting approximately 50 million people worldwide. In the seven major pharmaceutical markets alone—the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan—approximately 6.2 million adults were estimated to have active diagnosed epilepsy in 2025. Despite the introduction of numerous antiseizure medications over the past several decades, seizure freedom rates have remained largely unchanged, and approximately one-third of people with epilepsy continue to experience seizures despite treatment. This persistent treatment gap represents a major unmet need in epilepsy drug development.

Against this background, a discovery program was initiated to identify a new treatment candidate for epilepsy. During this effort, the 89th compound synthesized was designated YKP3089—the molecule that would later become XCOPRI® (cenobamate).

This presentation will revisit the origins of XCOPRI, beginning with the discovery of YKP3089 and following its progression through preclinical development. It will highlight key scientific findings, experimental challenges, and development decisions that shaped the compound during its earliest stages, offering a firsthand perspective on how YKP3089 began its journey from a discovery compound toward becoming XCOPRI.

Biography

Haein Shin joined SK in 2000 and has over 25 years of experience across pharmaceutical R&D, venture investment, business development, global partnering, and portfolio management.

Early in her career, she gained experience in venture investment, investing in approximately 20 biotechnology companies in Korea through a corporate fund. She later transitioned into business development, where she led the repositioning and partnering of SUNOSI® (solriamfetol). She subsequently led and completed global partnering activities for XCOPRI® (cenobamate), building on her earlier involvement in the discovery and preclinical development of the compound.

She currently leads portfolio management activities at SK Biopharmaceuticals, supporting strategic decision-making and prioritization across the company's R&D portfolio.

The Drug Development Odyssey: Clinical and Regulatory Perspectives



Sangmok Chung, Ph.D.
President
NatureCell America

Drug development is often described as a combination of linear and parallel sequences from discovery to approval. In practice it is closer to an odyssey: a long voyage shaped by scientific uncertainty, business pressure and shifting regulation. This presentation is to examine that journey from both the clinical and the regulatory side.

First, it argues that clinical development should be driven by strategy, and that strategy should center on the value of the program. Every decision should be judged by how it builds or preserves that value: target indication and population, trial design, endpoint selection, and the timing of regulatory interactions. The goal is to raise the probability of success and create a product that regulators, payers, partners and investors will all recognize as valuable. Second, it acknowledges that there is no textbook approach to development strategy. Each program is shaped by its modality, therapeutic area, competitive landscape, available resources and regulatory precedent. Case examples will show how teams can turn general principles into program-specific strategies, and how they can adapt when assumptions fail.

Finally, the presentation reviews the rapid changes taking place at the FDA under the current administration. It covers new policies, review programs and changing expectations for evidence, and what these shifts mean for sponsors planning development programs and regulatory interactions today.

Attendees will leave with a practical framework for building value-driven development strategies that can adapt to a changing regulatory environment.

Biography

Dr. Sang Mok Chung is President and Head of Global Clinical R&D at NatureCell America, based in Baltimore, Maryland. He has more than 25 years of experience across new medicinal product development, from R&D strategy and multi-regional clinical trials to regulatory strategy, product lifecycle management, and program and company acquisitions.

Before joining NatureCell America in 2025, Dr. Chung was Vice President of Regulatory Affairs at LG Chem Life Sciences USA in Boston. Earlier, he spent 21 years as a reviewer at the U.S. FDA's Center for Drug Evaluation and Research. His work has covered small molecules, peptides, oligonucleotides, therapeutic proteins, and cell and gene therapies. His therapeutic areas include metabolic and endocrine disease, oncology, respiratory and immunologic disorders, pain, and rare diseases.

Dr. Chung holds a Ph.D. in Pharmacokinetics from the University of Illinois at Chicago. He also completed the FDA Pharmacoepidemiology Certificate Program affiliated with the University of Pennsylvania.

EXPECT THE UNEXPECTED
(Lessons in Scientific Adaptability from the Clinical Development of Cenobamate)



Sunita Misra, M.D., Ph.D.
Chief Medical Officer
SK Life Science Inc.

Clinical development is often presented as a linear progression from preclinical research through phased clinical trials and regulatory approval. In practice, however, drug development rarely follows a predictable path. Unexpected safety findings, emerging clinical data, operational challenges, and evolving regulatory expectations can require development teams to reassess established plans and make difficult, evidence-based decisions. This presentation will use examples from the cenobamate (XCOPRI®) clinical development program to illustrate how SK Life Science navigated significant challenges before the product's initial FDA approval. It will also discuss more recent challenges encountered while generating evidence to support potential expansion of the current FDA-approved label. These experiences highlight the importance of scientific rigor, cross-functional collaboration, adaptability, and persistence in responding to unexpected findings. The presentation will offer practical lessons for transforming development obstacles into opportunities to strengthen the evidence base and advance meaningful new treatment options for patients.

Biography

Sunita Misra, M.D., Ph.D. joined the SK Life Science, Inc. team in 2023 initially supporting the ongoing clinical studies. Her deep experience as a clinician and researcher in pediatric epilepsy has enabled Dr. Misra to guide the organization's clinical development strategy. Currently, as Chief Medical Officer (CMO), Dr. Misra leads the development of SKLSI's clinical-stage programs from Phase 1 through post-marketing and provides scientific and medical information to stakeholders. Key components of the business function she leads include: Clinical Development, Clinical Operations, Clinical Pharmacology/Toxicology, Biometrics, and Medical Affairs.

Dr. Misra earned her Bachelor's degree at Emory University and her M.D. and Ph.D. in Pharmacology from Vanderbilt University. From there, she completed a pediatric neurology residency and fellowships in clinical neurophysiology and epilepsy at Baylor College of Medicine/Texas Children's Hospital. Dr. Misra then joined the faculty at Northwestern University as a physician-scientist. She cared for drug-resistant pediatric epilepsy patients at Ann & Robert H. Lurie Children's Hospital of Chicago and conducted research on genetic causes of pediatric epilepsy. Prior to joining the SK Life Science, Inc. team, Dr. Misra held a position at Neurelis, Inc. supporting CNS indications with a focus on epilepsy.

From Manufacturer to Patient: Navigating the Complex Pathways to Market Access



Kristina Stracco
Vice President, Market Access
SK Life Science Inc.

The U.S. pharmaceutical distribution and payer system is a highly complex, fragmented, and increasingly regulated ecosystem, where the path a product takes is far simpler than the path to patient access. While product moves relatively directly from manufacturer to patient, the financial picture is far more complicated. Discounts and fees flow across a web of wholesalers, pharmacies, PBMs, health plans, government programs, and patient assistance programs. Reimbursement dynamics, formulary requirements, and patient cost sharing coupled with an evolving regulatory environment focused on worldwide drug pricing, affordability, transparency, and government spending continuously reshape the economics and rules of access. These forces create growing pressure on Market Access to balance patient affordability, broad and sustainable coverage, regulatory requirements, and commercial performance. In this environment, having an effective therapy is only the starting point; successful commercialization increasingly depends on navigating a changing set of financial, regulatory, and access barriers to ensure the therapy ultimately reaches the patient.

Biography

Kristina Stracco joined SKLSI in 2019 and is currently the Vice President of Market Access, Trade, and Patient Services. With a career spanning multiple decades, Kristina has worked across several areas in Market Access and Financial Operations. She and her team are dedicated to ensuring that patients can both access and afford SKLSI's products. They work with a wide variety of stakeholders such as insurance companies, wholesalers, pharmacies, long term care facilities, and state and federal agencies.

From contracting with both national and regional payers as well as other institutions, to trade and supply chain management, and even to government pricing, Kristina brings a wide variety of experience to SKLSI. She's worked for both brand and generic pharmaceutical companies, including Xiromed, Alvogen, Xandoyne, Par Pharmaceutical, and Schering-Plough. Kristina has a bachelor's degree in both comparative religion and music from Emory University.

From Discovery to U.S. Commercialization: The XCOPRI® Journey



Keun Yong "Austin" Cho
Vice President, Commercial Operations
SK Life Science Inc.

Successful drug development does not end with regulatory approval. As a product approaches the market, companies must determine how to commercialize it, build the required capabilities, identify and prioritize customers, establish a differentiated brand position, and execute an effective launch.

Using XCOPRI® (cenobamate) as a case study, this presentation provides a practical overview of U.S. pharmaceutical commercialization. It follows the journey from the decision to commercialize directly in the U.S., through the establishment of SK Life Science's commercial organization and field force, to data-driven targeting and sales-force sizing. The presentation also examines how the XCOPRI launch strategy was developed. Market research across key epilepsy competitors and the XCOPRI target product profile helped identify an opportunity to differentiate on efficacy, particularly seizure freedom. Pre-launch market-shaping activities emphasized seizure freedom as an important treatment goal, followed by field execution focused on communicating XCOPRI's clinical evidence.
The XCOPRI experience illustrates how scientific innovation is translated into commercial strategy and ultimately into a successful U.S. product launch.

Biography
Keun Yong "Austin" Cho brings a wealth of expertise to SK Life Science as Vice President of Commercial.
Based in Paramus, NJ, Austin leads both the HQ Commercial and LSI Commercial Operations for SK's commercial products, playing a pivotal role in the company's global expansion and commercial strategy.
Prior to his current role, Austin served as Head of Commercial at SK Biopharmaceuticals, where he actively collaborated with partners abroad in launching and scaling products across international markets.
His leadership at headquarters encompassed oversight of commercialization programs, ensuring that innovative therapies reached patients in a timely and effective manner.
Earlier in his career, Austin gained extensive experience in global pharma commercialization in Pfizer and Samsung Bioepis. Drawing from regional and headquarters roles, he developed deep capabilities in go-to-market strategy, brand strategy, and cross-functional team leadership.

Effectively Utilizing Strategic Initiatives (BD) to Unlock Additional Growth



Woojin Choi
Vice President, U.S. Business Development
SK Life Science Inc.

In this segment, we will be covering the critical role of business development in the biopharma industry. We will look at trends & drivers in dealmaking appetite and how the most successful companies integrate dealmaking into their core strategy to enhance R&D productivity and improve shareholder returns. We will also examine the rising presence of China Biotech and the critical role it will play in the global biotech ecosystem. Lastly, we will cover the importance of SK Biopharma's recent in-licensing of Opakalim, a pivotal-stage epilepsy asset from Biohaven, and the new potassium channel MoA as the next generation of anti-seizure medications.

Biography

Woojin Choi leads the Business Development (BD) team and focuses on strategic partnerships & collaborations (including licensing and M&A) to drive growth at SKBP/SKLSI. With over two decades of investment banking experience from Wall Street, Woojin brings a differentiated skillset and experience that spans complex domestic and cross-border M&A, in-/out-licensing of clinical programs, asset/subsidiary divestitures, equity and debt capital raising, private placements, and specialty financings. Working alongside colleagues in different function groups and geographies, Woojin and the BD team will evaluate numerous projects simultaneously, carefully analyzing potential market opportunities, product/technology differentiation, and ultimate fit with SKBP/SKLSI's mid-/long-term portfolio strategy, among many other considerations.

SPONSORS

KASBP
Korean American Society in Biotech and Pharmaceuticals
재미한인제약인협회

SK biopharmaceuticals

25TH ANNIVERSARY

2026 FALL KASBP SYMPOSIUM

DRUG DISCOVERY AND DEVELOPMENT LANDSCAPE

EVOLUTION AND FUTURE HORIZONS

11/13 FRIDAY – 11/14 SATURDAY

DOUBLETREE BY HILTON HOTEL NEWARK AIRPORT
128 Frontage Rd., Newark, NJ 07114

FOR MORE INFORMATION, GO TO **KASBP.ORG**



KEYNOTE SPEAKER/ DAEWOONG ACHIEVMENT AWARD

David Chang

Co-Founder and Former President and CEO of Allogene Therapeutics



KASBP 25TH ANNIVERSARY HONORARY SPEAKER

Jin Keon Pai

Genexine, Inc.
Director (Independent)



Danny Lee

Founder and Principal Consultant DL BioInnovations LLC



Jong Sung Koh

CEO
GENOSCO



Jooyoung Lee

Senior Manager
Vertex Pharmaceuticals



Young Kwon Hong

Professor of Surgery
Harvard Medical School



Chongwoo Yu

Clinical Pharmacology Expert
Silver Spring, MD



Joon Hyung Kim

Senior Director, Clinical Project Lead,
GSK



Sean Kim

Vice President DMPK and Clinical Pharmacology
Recludix Pharma

SK biopharmaceuticals

SK life science

Together, we are Pioneering Innovations Transforming the Future of Central Nervous System Disorders and Cancer Care

SK Biopharmaceuticals is proud to be the first Korea-based company to independently discover, develop, and commercialize a molecule from inception to FDA-approval without partnering or out-licensing.

SK Biopharmaceuticals and SK Life Science, Inc. are part of SK Group, recognized as one of TIME's World's Best Companies of 2024.

Learn more and connect with us at **skbp.com** and **sklifesciencenc.com**

NOTE

KASBP NJ/NY
Korean American Society in Biotech and Pharmaceuticals
NEW JERSEY / NEW YORK

SK biopharmaceuticals